Back grey_arrow_rt.gif
 
 
Pharmasset HCV Update
 
 
  Pharmasset to Present at Canaccord Genuity Growth Conference
 
PRINCETON, N.J., Aug. 7, 2011 /PRNewswire/ --- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Canaccord Genuity Growth Conference to be held August 10 to 11, 2011 at the Intercontinental Hotel, Boston, Massachusetts. Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company at the Canaccord Genuity conference on Thursday, August 11, 2011 at 9:30 AM (ET). To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.
 
A replay of the webcasts will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website athttp://investor.pharmasset.com/events.cfm.
 
About Pharmasset
 
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections.Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Our research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates advancing in trials in various populations. Our pyrimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently under study in four Phase 2b trials in patients with HCV genotypes 1 through 6, including abbreviated duration interferon and interferon-free regimens. Our purine, PSI-938, an unpartnered guanosine nucleotide analog, recently reported safety and efficacy data from 14 days of monotherapy as well as 14 days in combination with the pyrimidine, PSI-7977. An SVR-endpoint study of the purine-pyrimidine combination is anticipated to begin in the third quarter of 2011. Mericitabine (RG7128) continues in three Phase 2b trials and one interferon-free trial being conducted through a strategic collaboration with Roche.

 
SOURCE Pharmasset, Inc.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org